05/02/2013 – GE: The Societal Value of an Enterprise by Roch Doliveux CEO UCB

Roch Doliveux, CEO of UCB

On “The Societal Value of an Enterprise”

Geneva, Thursday, May 2nd 2013, as of 6:00 PM

Dear Alumni,

It is with great pleasure that we invite you to this unique evening conference featuring Dr. Roch Doliveux (INSEAD MBA’81) on the “Societal Value of an Enterprise”.

rochDr. Doliveux, as Chief Executive Officer and Chairman of the Executive Committee of UCB – a leading global biopharmaceutical company headquartered in Belgium – will share his views and lead the discussion on how companies can contribute and deal with society at a higher level.

Under Dr. Roch Doliveux’s 8 years of leadership, UCB has been transformed from a diversified group to a leading focused patient-centric biopharmaceutical company. Join us to learn about UCB’s case study and understand how Dr. Doliveux applied societal values as an essential part of this transformation:

Swissôtel Metropole, 34, Quai Général Guisan, Geneva

6:00 pm – 6:30 pm:  Registration and Welcome Drink

6:30 pm – 7:30 pm:  Conference Dr. Roch Doliveux

7:30 pm – 9:00 pm:  Networking & Dinner Cocktail

Price:  75 CHF (Alumni Members) / 90 CHF (Non Members, Guests)

Please register & purchase your tickets online before Friday April 26th 2013 by clicking on the link below:


Please note that after this date no cancellation will be possible, that the number of places is limited and that we will handle registrations on a first come first served basis. For any inquiries, please send an email to [email protected].

We look forward to seeing you there,


Leila Ojjeh

President INSEAD Alumni Association Geneva

Jonas Larsson

INSEAD Alumni Association Geneva, committee member




Roch Doliveux is UCB’s Chief Executive Officer and Chairman of the Executive Committee since eight years

. He joined UCB in October 2003 as Head of UCB’s Pharmaceutical business and Deputy Chairman of the Executive Committee. Under his leadership, UCB was transformed from a diversified group to a focused patient-centric biopharmaceutical leader recognized for its attractive growth prospects and rich pipeline.

He is a member of the Board of Directors of UCB, a member of the Board of Stryker Corporation in the US, a member of the Board of the European Federation of Pharmaceutical Association (EFPIA), Chairman and member of the Board of the Innovative Medicines Initiative (IMI) which is a public-private partnership between the European Union and EFPIA, as well as a member of the Vlerick Business school. He also chairs the Caring Entrepreneurship Fund (King Baudouin Foundation), a philanthropic initiative which supports entrepreneurship in health and wellness. Doctor in Veterinarian Medicine from Maisons-Alfort (France), Roch Doliveux is also Laureate of the Faculty of Medicine, Créteil, and holds an MBA with distinction from INSEAD (France). Roch Doliveux was awarded the Doctor Honoris Causa degree of the University of Liège (Belgium) in October 2011 and was bestowed the title of Commander of the Order of the Crown of Belgium in November 2012. He first joined the pharmaceutical industry with Ciba-Geigy (now Novartis) in Switzerland, Peru and France, and then with Schering-Plough Corporation in various positions in Belgium, France and the US, including President of Schering-Plough International. Before joining UCB, Roch Doliveux was Chief Executive Officer of Pierre Fabre Pharmaceuticals

P1020369_2 P1020370_2 P1020371_2 P1020373_2 P1020375_2 P1020376_2 P1020377_2 P1020378_2 P1020379_2 P1020380_2 P1020382_2 P1020383_2 P1020384_2 P1020385_2 P1020386_2 P1020387_2 P1020389_2  P1020392_2P1020393_2P1020388_2  P1020394_2 P1020398_2 P1020399_2 P1020401_2 P1020403_2 P1020410_2 P1020413_2 P1020414_2  P1020416_2 P1020418_2 P1020423_2 P1020424_2

04/09/2013 – GE:How to Become an Angel in Suisse Romande?

INSEAD Alumni Association Geneva, IPEN, A3 Angels and

EPFL Alumni Association welcome you to…




Joint Presentation, Panel Discussion & Cocktail

“How to become an Angel in Suisse Romande”

On Tuesday, April 9th 2013 from 18:00 – 21:30, Geneva, UBS Acacias

Switzerland is a hot-bed for the development of new, advanced technologies and ranked first in the INSEAD Global Innovation Index 2012. While it leads in innovation performance, it lags in mobilizing early-stage investment to allow new ventures to thrive. Angel investors can play a key role in providing start-ups with capital, expertise and access to their networks. In the US, angel investment is highly developed and accounts for as much as all venture capital funds combined.

What is the situation in Suisse Romande? How easy is it to access Angel Funding for start-ups? What role do they play in their success path? What is the ideal profile of an Angel Investor and/or Mentor? Come and join us to get a full picture ofthe Angels landscape in Suisse Romande. We will first present Angel networks and crowd-funding organisations in the region, to then share real-life experiences through a panel discussion featuring 2 highly successful entrepreneurs – Pedro Bados (CEO Nexthing) and Marco Boella (CEO Lemoptix) from the EPFL Parc Scientifique and 1 famous entrepreneur and serial angel investor, Martin Velasco. We will then inform on future Angel focused events, and end up the event with a networking cocktail.

We look forward to welcoming you to this first Joint Event between EPFL & INSEAD Alumni Associations, A3 Angels and IPEN with the objective to join forces to promote innovation and entrepreneurship in the region.


Odile Batty, President of EPFL Alumni Association (EPFL, INSEAD Alumna)

Leila Ojjeh, President INSEAD Alumni Association Geneva (EPFL, INSEAD Alumna)



Claude Florin, President of A3 Angels, partner at Venture Concept, member of CTI program for start-ups (EPFL Alumnus)

Panel Discussion & Q&A:
Pedro Bados, President and CEO of Nexthink (EPFL Alumnus)
Marco Boella, CEO of Lemoptix
Martin Velasco, leading European “Business Angel”, board member Anecova, Sumerian, Cocomore, and Aridhia (EPFL, INSEAD Alumnus)
Kelly Richdale (Moderator), VP Marketing and Sales, ID Quantique, ex-founder of A4 vision (INSEAD Alumna)


Next Steps:

Colin Turner, currently with greenTEK ventures and previously with Inventages (the “Nestle Fund”), Intel Capital and Motorola (INSEAD Alumnus)


When: Tuesday, April 9 2013
18:00 – 18:30 Registration
18:30 – 20:00 Presentation, Panel and Q&A
20:00 – 21:30 Cocktail
Where: Main Auditorium – UBS Acacias – 35, rue des Noirettes, 1227 Carouge, Geneva

UBS Parking facilities (beneath the venue) are available for use by attendees.

We thank UBS for their support in welcoming us and offering their facilities for this event.


Price: 50 CHF (INSEAD IAA & EPFL Alumni Members) / 75 CHF (Non Members & Guests)

You’re welcome to invite a guest of your choice.

Registration online – latest by Wednesday April 4th 2013 at 12am using the link below:


Please note that after this date no cancellation will be possible.


Pedro Bados (Panelist): Pedro is one of the Nexthink co-founders and is President and CEO. He brings his leadership and vision to lead the organization and ensure its continuous growth. Pedro holds an M.Sc. in Electrical Engineering and Computer Science from EPFL, Switzerland and Universidad de Zaragoza, Spain. While at EPFL he developed the first real-time end-user monitoring technology and he is the author of two patents on behavior modeling that form part of Nexthink’s core technology. Pedro is currently a Board member of the Alpine chapter of the Young Presidents’ Organization (YPO), he serves on the Board of several start-ups and he’s an occasional lecturer at EPFL on entrepreneurship and new technologies.

 marcoMarco Boella (Panelist): Marco Boella is Chief Executive Officer of Lemoptix and is in charge of the overall strategy and development of the company. Prior to co-founding Lemoptix, Marco held several leadership positions in sales, marketing and general management within global corporations, such as HP and Nokia, as well as IT, telecommunications and software start-ups, such as Solid Information Technology (acquired by IBM), CNET Channel, Inforay and Applic8. In addition to his wide industry experience, he has a very strong track record in developing new businesses from scratch, leading geographically dispersed teams and driving business growth across multi-country regions. Marco holds an M.Sc in Mechanical Engineering and Computer Science from the University of Technology, Helsinki, Finland.

 martinMartin Velasco (Panelist): Martin Velasco is considered a leading European “Business Angel” by the Wall Street Journal and one of the leaders of European change by Business Week. He serves on the Board of several high-tech companies such as Anecova, ART – In Vivo Fertilization, Sumerian, IT Analytics, Cocomore, Digital Communications Agency & IT Services and Aridhia, Health Informatics. Martin is the Founder and Chairman of Infantia Foundation, a philanthropic organization aiding children in the developing world. He is member of the Board of BlueOrchard, the leading private microfinance investment advisory company; Vice President of the Board of the Foundation EPFL+ and Vice Chairman of the European Tech Tour Association.

 Claude Floriclauden (Introduction): Claude Florin is President of A3 Angels, a business angel club at the Swiss Federal Institute of Technology providing seed investment. He is a partner at Venture Concept focusing on international business development and investment advisory. He is a member of the Swiss Commission for Technology and Innovation program for start-ups program. Previously, he held management positions at Hewlett-Packard‘s Communications and Media Solutions and HP’s Medical Products Group (now Philips Healthcare). He has led 6 technology business unit launches growing annual sales from $10M to 100M and established ventures in telecoms (Alcatel, Cisco, HP, Ericsson, Nokia Siemens Networks, NEC) and MedTech (Bayer, General Electric, Philips, Siemens). Claude has an MSEE degree in Electrical Engineering from EPFL and executive education certificates from IMD and Harvard Business School on managing innovation and venture capital investments.

 Kelly Richdale (Moderator): Kelly is VP Marketing & Sales for ID Quantique, a Geneva-based company specializkellying in quantum cryptography and network encryption for financial institutions, enterprises and governments. She is a serial entrepreneur, having founded a television production company in Russia in 1994 and co-founded A4Vision specializing in 3D facial recognition in 2000. During her time at A4Vision she participated in fund raising from both angel investors and VCs, as well as in the acquisition of A4Vision by Bioscrypt in 2007. In 2008 Bioscrypt was acquired by L1 Identity Solutions. She holds an MBA from INSEAD (Fontainebleau) and a degree in modern languages (Russian & German) from Cambridge University.

Colphotoin Turner (Next Steps): Colin has 20 years of experience in venture capital, operations, fund-raising and as legal counsel. While at Inventages, the “Nestle Fund” (Geneva, Switzerland), Intel Capital (Swindon, UK, Silicon Valley, USA and Munich, Germany) and Motorola (London, UK and Chicago, USA) Colin worked across 5 continents on over 200 investments, acquisitions, listings and divestments in companies operating in high-tech, health-care and bio-technology. Colin earned an MBA from INSEAD and qualified as a lawyer in the United Kingdom.


IMG_4987 IMG_4996 IMG_5027 IMG_5044 IMG_5071 IMG_5073 IMG_5082 IMG_5107 IMG_5142 IMG_5229 IMG_5314 IMG_5468Joint Event INSEAD-EPFL, UBS Acacias Geneva, 9/4/13